PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF OAT1/3 ACTIVITY IN PATIENTS WITH CHRONIC KIDNEY DISEASE.

被引：0
|
作者：
Dubinsky, S. [1 ]
Malik, P. [1 ]
Edginton, A. [1 ]
机构：
[1] Univ Waterloo, Waterloo, ON, Canada
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2022年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P-054
引用
收藏
页码：S19 / S19
页数：1
相关论文
共 50 条
  • [21] Application of physiologically-based pharmacokinetic modeling to explore the role of kidney transporters in renal reabsorption of perfluorooctanoic acid in the rat
    Worley, Rachel Rogers
    Fisher, Jeffrey
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2015, 289 (03) : 428 - 441
  • [22] Physiologically-based Pharmacokinetic Modeling of Atorvastatin Acid and Major Metabolites in Stable Kidney Transplant Recipients with Diabetes Mellitus
    Macwan, Joyce S.
    Bolger, Michael B.
    Akhlaghi, Fatemeh
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S118 - S119
  • [23] APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING TO BOSUTINIB PHARMACOKINETICS: PREDICTION OF DRUG-DISEASE INTERACTION IN ORGAN DYSFUNCTION PATIENTS.
    Ono, C.
    Hsyu, P.
    Abbas, R.
    Loi, C.
    Yamazaki, S.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S74 - S74
  • [24] Physiologically-Based Pharmacokinetic Modeling for Drug Dosing in Pediatric Patients: A Tutorial for a Pragmatic Approach in Clinical Care
    van der Heijden, Joyce E. M.
    Freriksen, Jolien J. M.
    de Hoop-Sommen, Marika A.
    Greupink, Rick
    de Wildt, Saskia N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (05) : 960 - 971
  • [25] PHARMACOGENETICS GUIDED PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF OXYCODONE AND ITS METABOLITES FOR CHRONIC PAIN MANAGEMENT (CPM).
    Samant, T. S.
    Schmidt, S.
    Trescot, A. M.
    Norton, S.
    Palmer, M.
    Lesko, L. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S91 - S92
  • [26] Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin
    Butrovich, Morgan A.
    Tang, Weifeng
    Boulton, David W.
    Nolin, Thomas D.
    Sharma, Pradeep
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (08): : 1018 - 1029
  • [27] Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients
    Malik, Paul R., V
    Edginton, Andrea N.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (11): : 835 - 844
  • [28] Prediction of CYP3A inhibition using physiologically-based pharmacokinetic modeling and trial simulation.
    Chien, JY
    Wrighton, SA
    Hall, SD
    Lilly, E
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P56 - P56
  • [29] POPULATION PHARMACOKINETIC MODELING AND SIMULATION TO SUPPORT QUALIFICATION OF ENDOGENOUS BIOMARKER OF OAT1/3 RENAL TRANSPORTERS.
    Ahmad, A.
    Ogungbenro, K.
    Jacobs, F.
    Kunze, A.
    Snoeys, J.
    Rostami-Hodjegan, A.
    Galetin, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S94 - S95
  • [30] The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling
    Ghoneim, Amira M.
    Mansour, Suzan M.
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 1469 - 1479
12345